11 Jul 2021 NITROSAMINE CONTENT IN ANTIHYPERTENSIVE MEDICATION, THE POSSIBLE CANCER DEVELOPMENT AND THE BIG PHARMA PROTECTION – A NEVER ENDING STORY. Visit: https://www.gmp-compliance.org/gmp-news/sartan-medicinal-products-emas-assesment-report-defines-nitrosamine-limits-and-reporting-deadlines